RxDoctor Payments Data

Christopher McKibbin, MD

Internal Medicine · Hampstead, NCNPI 1386088607

Payments from drug & device makers

$356in general payments, 2019–2025

Across 24 payments — averaging $14.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$45
  • Medtronic$44
  • Johnson & Johnson$42
  • Boehringer Ingelheim$37
  • Pfizer$37
  • Novo Nordisk$32
  • plus $119 from 8 others

What the payments were for

  • Food & beverage$356100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$356 in reported general payments places this provider in the 60th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$153,448
Medicare patients
287
Services billed
4,571

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban44$69,615
JanuviaSitagliptin Phosphate44$63,693
OzempicSemaglutide38$61,150
XareltoRivaroxaban43$57,114
MounjaroTirzepatide24$37,351
JardianceEmpagliflozin11$19,238
FarxigaDapagliflozin Propanediol12$17,668
Stiolto RespimatTiotropium Br/Olodaterol Hcl13$13,551
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog14$7,549
Atorvastatin Calcium680$7,323
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr20$7,251
Breo ElliptaFluticasone/Vilanterol11$4,306
Rosuvastatin Calcium221$3,670
Losartan Potassium255$2,774
Lisinopril324$2,366

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$37$69,61544 claims
MerckJanuvia$17$63,69344 claims
Novo NordiskOzempic$32$61,15038 claims
Johnson & JohnsonXarelto$42$57,11443 claims
Lilly USA, LLCMounjaro$12$37,35124 claims
Boehringer IngelheimJardiance, Stiolto Respimat$37$32,78924 claims
GSKAnoro Ellipta, Breo Ellipta$45$11,55731 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Hampstead

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →